Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

9.00
-0.3300-3.54%
Post-market: 9.350.3500+3.89%18:59 EDT
Volume:34.31K
Turnover:313.13K
Market Cap:86.28M
PE:14.06
High:9.53
Open:9.23
Low:8.94
Close:9.33
52wk High:29.98
52wk Low:6.53
Shares:9.59M
Float Shares:7.29M
Volume Ratio:0.64
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6400
EPS(LYR):0.0175
ROE:19.64%
ROA:-42.25%
PB:1.95
PE(LYR):514.20

Loading ...

Seres Shares Down After Co Pauses Drug Development, Lays Off Workers

Dow Jones
·
Feb 12

BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases

Reuters
·
Feb 12

Seres Therapeutics Cuts Workforce by 30% and Shifts Focus to Early-Stage Programs

Reuters
·
Feb 12

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

THOMSON REUTERS
·
Feb 12

Seres Therapeutics Inc: Company's Runway Extension Actions, Including Reducing Workforce by Approximately 30%

THOMSON REUTERS
·
Feb 12

Seres Therapeutics Inc: Expects to Extend Its Cash Runway Through Q3 of 2026

THOMSON REUTERS
·
Feb 12

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
Feb 12

Seres Therapeutics Reports SER-155 Reduces Bloodstream Infections in Stem Cell Transplant Patients

Reuters
·
Jan 06

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

GlobeNewswire
·
Jan 06

BUZZ-Seres Group's Hong Kong shares jump after joining stock connect program

Reuters
·
Dec 01, 2025

Seres Therapeutics Reports Positive Q3 2025 Results

TIPRANKS
·
Nov 06, 2025

Seres Therapeutics Q3 2025 Earnings Call Summary and Q&A Highlights: SER-155 Progress and Strategic Partnerships

Earnings Call
·
Nov 06, 2025

Seres (MCRB) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 06, 2025

Analysts’ Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

TIPRANKS
·
Nov 06, 2025

Seres Therapeutics Q3 net income $8.2 mln, reverses loss

Reuters
·
Nov 05, 2025

Seres Therapeutics Q3 EPS USD 0.94

Reuters
·
Nov 05, 2025

Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate

Benzinga
·
Nov 05, 2025

Seres Therapeutics Inc: Expanding Understanding of Broader Ser-155 Therapeutic Opportunity, Expect Obtaining Initial Efficacy Results in Early 2026

THOMSON REUTERS
·
Nov 05, 2025

Seres Therapeutics Inc - Expects to Fund Operations Through Q2 2026 After Cost Reductions

THOMSON REUTERS
·
Nov 05, 2025

Seres Therapeutics Q3 Net Income USD 8.204 Million

THOMSON REUTERS
·
Nov 05, 2025